Golden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
Golden State Medical Supply is recalling 1,200 bottles of Carbamazepine 200mg tablets due to tablets containing black specks.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves CGMP deviations (black specks) without reported illnesses or injuries, fitting the criteria for a moderate severity score.
Plain-English summary
Golden State Medical Supply Inc. is recalling 1,200 bottles of Carbamazepine Tablets, USP, 200mg. The product is marketed by GSMS, Incorporated, in Camarillo, CA, and manufactured by Taro Pharmaceutical Industries Ltd. The recall covers 100-count and 1,000-count bottles distributed nationwide in the United States.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations, specifically the presence of black specks in the tablets. Affected lots include GS067429, GS068091, GS067430, and GS068090, all with an expiration date of May 31, 2028.
Consumers and healthcare providers should check their inventory for the specific NDCs (51407-215-10 and 51407-215-01) and lot numbers listed above. If the product is found, it should be quarantined and not administered to patients.
The recalled product
- Product
- CARBAMAZEPINE (CARBAMAZEPINE)
- Brand
- CARBAMAZEPINE
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug — Prescription Drug
- Affected units
- 1,200
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot #: a) GS067429
- GS068091
- Exp 5/31/2028
- b) GS067430
- GS068090
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CARBAMAZEPINE
- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- ModerateCarbamazepine extended release tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-08
- ModerateCarbamazepine tablets recalled for failed dissolution specifications
FDA (Drugs) · 2022-01-19
- ModerateCarbamazepine 200mg Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2021-09-29
- ModerateTorrent Pharma Recalls Carbamazepine Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2020-06-10
Same manufacturer · Golden State Medical Supply Inc.
See all →- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- HighBaclofen tablet bottles recalled over the presence of foreign tablets
FDA (Drugs) · 2025-12-24
- ModerateNiacin extended release tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-11-26
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19